南美洲和中美洲药物基因组学市场预测至 2028 年 - COVID-19 影响和区域分析技术（PCR、测序、微阵列、凝胶电泳、质谱等）、应用（药物发现、肿瘤学、神经病学和精神病学、疼痛管理、心血管疾病等）和最终用户（医院和诊所、生物制药公司、CRO 和 CDMO 等）
No. of Pages: 143 | Report Code: TIPRE00028880 | Category: Life Sciences
No. of Pages: 143 | Report Code: TIPRE00028880 | Category: Life Sciences
中南美洲药物基因组学市场预计将从 2021 年的 2.948 亿美元增至 2028 年的 5.9135 亿美元。预计从 2021 年起复合年增长率为 10.5%到2028年。
推动该市场增长的关键因素是慢性病患病率不断上升、精准医疗需求激增、药物基因组学研究活动资金的增加。然而，熟练专业人员的短缺预计将限制预测期内的市场增长。
许多老年人（>60%）患有两种或多种慢性病。双胞胎研究已证实，基因会导致慢性疾病，如心血管疾病 (CVD)、糖尿病、肥胖、类风湿性关节炎、阿尔茨海默病 (AD) 和抑郁症。利用全基因组关联研究 (GWAS) 的分子遗传数据，现在可以测量这些慢性疾病的个体风险。
动脉粥样硬化、心绞痛、急性心肌梗死等心血管疾病，由于忙碌的生活方式导致死亡率很高。根据世界卫生组织 (WHO) 提供的数据，CVD 是导致死亡的主要原因，每年夺去约 1790 万人的生命。糖尿病是危及生命的疾病之一，无法进行功能性治愈。所有类型的糖尿病都会导致身体不同部位出现各种并发症，并增加过早死亡的风险。心脏病、中风、肾衰竭、截肢、视力丧失和神经损伤是与糖尿病相关的主要并发症。糖尿病病例的显着增加导致了改变人们生活的并发症。据国际糖尿病联合会（IDF）统计，2017年北美报告有4600万糖尿病患者，预计到2045年将达到6200万。
该数据还报告称，2017 年约有 4.25 亿人患有糖尿病，预计到 2045 年将达到 6.29 亿。在预测期内，该疾病的患病率将增加约 35%。据阿尔茨海默病协会称，2020年，全球有5500万人患有阿尔茨海默病。随着慢性疾病的迅速增加，用于治疗危及生命的疾病的基因组学研究在过去五年中取得了迅速进展，推动了市场的增长。
Strategic insights for South and Central America Pharmacogenomics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 294.80 Million |
| Market Size by 2028 | US$ 591.35 Million |
| Global CAGR (2021 - 2028) | 10.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 技术
|
| Regions and Countries Covered | 南美洲和中美洲
|
| Market leaders and key company profiles |
The regional scope of South and Central America Pharmacogenomics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The South and Central America Pharmacogenomics Market is valued at US$ 294.80 Million in 2021, it is projected to reach US$ 591.35 Million by 2028.
As per our report South and Central America Pharmacogenomics Market, the market size is valued at US$ 294.80 Million in 2021, projecting it to reach US$ 591.35 Million by 2028. This translates to a CAGR of approximately 10.5% during the forecast period.
The South and Central America Pharmacogenomics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South and Central America Pharmacogenomics Market report:
The South and Central America Pharmacogenomics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South and Central America Pharmacogenomics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South and Central America Pharmacogenomics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South and Central America Pharmacogenomics Market
